登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，5月7日，COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-09

  • Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

    Giulio Cavalli, MD

    Giacomo De Luca, MD

    Corrado Campochiaro, MD

    Emanuel Della-Torre, MD

    Marco Ripa, MD

    Diana Canetti, MD

    et al.

    Show all authors

    Published:May 07, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30127-2

    Background

    Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial in this patient population.

  • 原文来源：https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext
43浏览量
原文链接
相关报告

  • 《LANCET，5月29日，Anakinra for severe forms of COVID-19: a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-30
    • Anakinra for severe forms of COVID-19: a cohort study Thomas Huet, MD Hélène Beaussier, Pharm D Olivier Voisin, MD Stéphane Jouveshomme, MD Gaëlle Dauriat, MD Isabelle Lazareth, MD et al. Show all authors Published:May 29, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30164-8 Summary Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. Methods The Ana-COVID study included a prospective cohort from Groupe Hospitalier Paris Saint-Joseph (Paris, France) and a historical control cohort retrospectively selected from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020. Patients were included in the prospective cohort if they were aged 18 years or older and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneumonia on chest x-ray or lung CT scan. The other inclusion criteria were either laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and either an oxygen saturation of 93% or less under oxygen 6 L/min or more, or aggravation (saturation ≤93% under oxygen 3 L/min) with a loss of 3% of oxygen saturation in ambient air over the previous 24 h. The historical control group of patients had the same inclusion criteria. Patients in the anakinra group were treated with subcutaneous anakinra (100 mg twice a day for 72 h, then 100 mg daily for 7 days) as well as the standard treatments at the institution at the time. Patients in the historical group received standard treatments and supportive care. The main outcome was a composite of either admission to the intensive care unit (ICU) for invasive mechanical ventilation or death. The main analysis was done on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra).
    32浏览量
    原文链接

  • 《Lancet，5月28日，Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-29
    • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M Kuderer, MD † Toni K Choueiri, MD † Dimpy P Shah, PhD † Yu Shyr, PhD † Samuel M Rubinstein, MD Donna R Rivera, PharmD et al. Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9 Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
    139浏览量
    原文链接